HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.
IPO Year: 2021
Exchange: NASDAQ
Website: heartbeam.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/20/2021 | $9.00 | Speculative Buy | Benchmark |
Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00